Watchfuf waiting for Rectal Carcinoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Ascension St. John Hospital, Detroit, MI
Rectal Carcinoma+1 More
Watchfuf waiting - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.

Eligible Conditions

  • Rectal Carcinoma

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: three years

three years
Local recurrence free survival
Quality of life using LARS score

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Watchful Waiting
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Watchfuf waiting · No Placebo Group · Phase 2

Watchful Waiting
Other
Experimental Group · 1 Intervention: Watchfuf waiting · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: three years
Closest Location: Ascension St. John Hospital · Detroit, MI
Photo of Detroit 1Photo of Detroit 2Photo of Detroit 3
2020First Recorded Clinical Trial
2 TrialsResearching Rectal Carcinoma
11 CompletedClinical Trials

Who is running the clinical trial?

Ascension South East MichiganLead Sponsor
17 Previous Clinical Trials
3,160 Total Patients Enrolled
1 Trials studying Rectal Carcinoma
15 Patients Enrolled for Rectal Carcinoma
Amr Aref, MDPrincipal InvestigatorAscension St. John Hospital

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.